Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
Although investors are aware of this, market expectations are still high. Biogen will face ongoing challenges as these expectations are adjusted to more realistic levels.Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year.
Needham下調了渤健公司（納斯達克：BIIB）的評級，指出公司在未來一年內缺乏有利的催化因素。
Alzheimer's drug Leqembi's (lecanemab) sales growth is expected to stay gradual without a sharp increase in the near future. The analyst remarked that the physician feedback and expert opinions indicate this slow pace will continue.
阿爾茨海默病藥物Leqembi（lecanemab）的銷售增長預計將保持緩慢，近期不會有大幅增長。分析師表示，醫生反饋和專家意見表明這種緩慢的進展將會持續。
Leqembi's third-quarter global in-market sales were approximately $67 million, including U.S. in-market sales of approximately $39 million.
Leqembi第三季度的全球市場銷售額約爲6700萬，包括美國市場銷售額約爲3900萬。
Although investors are aware of this, market expectations are still high. Biogen will face ongoing challenges as these expectations are adjusted to more realistic levels.
儘管投資者對此有所了解，但市場期望仍然很高。渤健公司將面臨持續的挑戰，因爲這些期望需要調整到更現實的水平。
In a positive move, last week, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Eisai Co., Ltd (OTC:ESALY) and Biogen's lecanemab for early Alzheimer's disease.
在一個積極的舉措中，上週，歐洲藥品管理局（EMA）人用藥品委員會（CHMP）推薦批准Eisai Co., Ltd（場外交易：ESALY）和渤健公司的lecanemab用於早期阿爾茨海默病治療。
Needham projects Skyclarys' fourth-quarter sales to reach approximately $116 million and $608 million for 2025. This aligns with management's comments suggesting that U.S. sales growth may be uneven, while international growth could be slower due to pricing negotiations and a gradual increase in the number of patients on treatment.
Needham預計Skyclarys的第四季度銷售額將達到約11600萬，並在2025年達到60800萬。這與管理層的評論一致，表明美國的銷售增長可能不均勻，而國際增長可能因價格談判和接受治療患者數量的逐步增加而放緩。
Revenues from Skyclarys, acquired via Reata acquisition, reached $102.3 million during the quarter.
通過Reata收購獲取的藥品Skyclarys在本季度達到10230萬美元的收入。
Needham writes that revenues are expected to remain flat or decline slightly until 2026, as it will take time for new products like Leqembi, Skyclarys, and Zurzuvae to grow enough to offset the drop in existing business.
Needham指出，預計收入將在2026年前保持平穩或略微下降，因爲新產品如Leqembi、Skyclarys和Zurzuvae需要時間發展到足以彌補現有業務下降的程度。
Postpartum depression drug Zurzuvae's third-quarter sales reached $22 million.
產後抑鬱症藥物Zurzuvae在第三季度的銷售額達到了2200萬美元。
Needham has downgraded the stock from Buy to Hold with no price target, compared to $270 earlier.
Needham將該股票評級從買入下調至持有，沒有設定價格目標，之前的目標是270美元。
Revenues are projected to fall by a small percentage in 2024, remain stable in 2025, and increase by about 3% in 2026, assuming continued growth from key product launches.
預計2024年的收入將下降一個小百分比，2025年保持穩定，2026年增加約3%，假設關鍵產品發佈持續增長。
Operating margins are anticipated to improve by 80 basis points in 2025, driven by the Fit for Growth program, though this is already widely expected.
預計到2025年，運營利潤率將提高80個點子，主要受益於增長適應計劃，儘管這一點已經廣泛預期。
Business development could support growth in the short to medium term, but the timing and nature of such deals are hard to predict.
業務發展可以在短期到中期內支持增長，但此類交易的時機和性質難以預測。
Price Action: BIIB stock is down 1.15% at $158.15 at the last check on Monday.
價格動態：在週一的最後檢查中，BIIb股票下跌1.15%，報158.15美元。
- Why Is Medical Device Giant Boston Scientific Stock Trading Higher On Monday?
- 爲什麼器械巨頭波士頓科學的股票在週一上漲？
譯文內容由第三人軟體翻譯。
